4.6 Review

Epigenome-metabolome-microbiome axis in health and IBD

Journal

CURRENT OPINION IN MICROBIOLOGY
Volume 56, Issue -, Pages 97-108

Publisher

CURRENT BIOLOGY LTD
DOI: 10.1016/j.mib.2020.08.005

Keywords

-

Categories

Funding

  1. Canadian Institute of Health Research (CIHR) postdoctoral fellowship
  2. Kenneth Rainin Foundation
  3. NIH [R01DK119996, R21AI144877]
  4. Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award) [UL 1TR002541]
  5. Harvard University

Ask authors/readers for more resources

Environmental triggers in the context of genetic susceptibility drive phenotypes of complex immune disorders such as Inflammatory bowel disease (IBD). One such trigger of IBD is perturbations in enteric commensal bacteria, fungi or viruses that shape both immune and neuronal state. The epigenome acts as an interface between microbiota and context-specific gene expression and is thus emerging as a third key contributor to IBD. Here we review evidence that the host epigenome plays a significant role in orchestrating the bidirectional crosstalk between mammals and their commensal microorganisms. We discuss disruption of chromatin regulatory regions and epigenetic enzyme mutants as a causative factor in IBD patients and mouse models of intestinal inflammation and consider the possible translation of this knowledge. Furthermore, we present emerging insights into the intricate connection between the microbiome and epigenetic enzyme activity via host or bacterial metabolites and how these interactions fine-tune the microorganism-host relationship.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available